US › Healthcare

Processa Pharmaceuticals Inc (PCSA)

US · Healthcare · Biotechnology

$2.12-0.47%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-3.4M
Profit YoY
-19.1%
EPS
$-1.75
EPS estimate
$-2.00

EPS came in at -1.75 against a street estimate of -2.00 — a beat of 12.5%.

Key statistics

Market cap
$6.0M
Forward P/E
0.0
P/B
2.34
Book value
$0.95
EPS (TTM)
$-4.07
52-week high
$14.25
52-week low
$1.67
50-day MA
$2.29
200-day MA
$3.75
Beta
0.99

Analyst view

Analysts rate Processa Pharmaceuticals Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $25.00.

Shareholding

Insiders
14.90%
Institutions
10.24%

Largest institutional holders

FundStake
Connective Capital Management LLC2.56%
Stonepine Capital Management Llc1.99%
Geode Capital Management, LLC0.90%
Vanguard Group Inc0.85%
Vanguard Capital Management, LLC0.46%
Vanguard Fiduciary Trust Co0.39%
UBS Group AG0.09%
Tower Research Capital LLC0.03%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Processa Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.